Trutakna (atacicept) — accelerated approval for IgA nephropathy (Jul 7 2026)
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/20/26) through T+5. Run-up high $49.1 on 1/21/26, low $31.26 on 6/4/26 (T-120 to T-1). FDA decision 7/7/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-07-07
OutcomeApproved
Drug / candidateAtacicept - (ORIGIN 3)
IndicationIgA Nephropathy
CompanyVera Therapeutics
Market-cap tierMid
120-day run-up (T-120→T-1)-13.6%
Cohort decision-day move (history)±2% median
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction.